The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
The custom-made software will also allow Twist's biopharmaceutical customers to access a proprietary G-protein coupled receptor target library.
Researchers discuss the need for antibody standards at a meeting, NPR reports.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The partners will collaborate on point-of-care tests for validating the identity and activity of biologics and biosimilars.
The move marks a step in the effort to improve antibody quality as the life science community becomes increasingly aware of the problem of faulty reagents.
The partners will continue to develop an integrated sequence and knowledge database to support Pierre Fabre's therapeutic antibody development efforts.
Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.
Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.
Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.
In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.